Inhaled amikacin for pneumonia treatment and dissemination prevention

Ana Motos, Hua Yang, Gianluigi Li Bassi, Minlan Yang, Andrea Meli, Denise Battaglini, Roberto Cabrera, Joaquim Bobi, Francesco Pagliara, Gerard Frigola, Marta Camprubí‑Rimblas, Laia Fernández‑Barat, Montserrat Rigol, Antoni Ferrer‑Segarra, Kasra Kiarostami, Daniel Martinez, David P. Nicolau, Antonio Artigas, Paolo Pelosi, Jordi Vila, and Antoni Torres Critical Care Medicine DOI: 10.1186/s13054-023-04331-x

Background: Pseudomonas aeruginosa pneumonia is commonly treated with systemic antibiotics to ensure adequate treatment of multidrug resistant (MDR) bacteria. However, intravenous (IV) antibiotics often achieve suboptimal pulmonary concentrations. We therefore aimed to evaluate the effect of inhaled amikacin (AMK) plus IV meropenem (MEM) on bactericidal efficacy in a swine model of monolateral MDR P. aeruginosa pneumonia.